Compare iShares MSCI South Korea ETF (EWY) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI South Korea ETF trades at $148.89 (market cap $24.38B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: iShares MSCI South Korea ETF is far larger — about 6.5× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 48 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWY | TNGX | |
|---|---|---|
Market Cap | $24.38B | $3.75B |
Volume | 22,329,675 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $32.90 |
52-Week Low | $85.17 | $7.50 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, is trading at $166.56, down 2.16% amid bearish technical signals. The ETF faces pressure from rising US yields and oil prices impacting South Korean tech stocks, though corporate earnings remain resilient with strong AI memory demand driving performance. Technical indicators show oversold conditions with RSI at 21.77 suggesting potential bounce.
Outlook remains cautious due to concentrated exposure to Samsung and SK hynix, making EWY highly sensitive to semiconductor cycle volatility. While AI infrastructure spending provides growth catalyst, macroeconomic headwinds and profit-taking near 7,000 KOSPI level present near-term risks for investors.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
